Jacquelyn Meldrum, NP
Registered Nurse · Brownstown, MINPI 1639534373
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,503 of the $5,085 with a category attached, or 88.6%. 24 manufacturers reported payments, led by Dexcom, Inc. at 30.2% of the total. Reporting peaked in 2023 at $1,455 and has fallen 52.0% since, to $699 in 2025. Among registered nurse clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$2K
- Medtronic$1K
- Lilly USA, LLC$512
- Novo Nordisk$295
- Tandem Diabetes Care, Inc.$225
- Abbott$188
- plus $905 from 18 others
What the payments were for
- Travel & lodging$58211%
- Food & beverage$4,50389%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 155 | $1,534 |
| Medtronic | 52 | $1,426 |
| Lilly USA, LLC | 32 | $512 |
| Novo Nordisk | 28 | $295 |
| Tandem Diabetes Care, Inc. | 22 | $225 |
| Abbott | 10 | $188 |
| Boehringer Ingelheim | 10 | $174 |
| Antares Pharma, Inc. | 9 | $161 |
| AstraZeneca | 9 | $118 |
| Mannkind Corporation | 4 | $75 |
| Nevro Corp. | 2 | $58 |
| Amarin Pharma, Inc. | 3 | $50 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Halozyme Inc | 2 | $37 |
| BD | 2 | $35 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Cequr Corporation | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Embecta Corp. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$497
How this compares
$5,085 in reported general payments places this provider in the 95th percentile of 121 registered nurse providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 482 | $704,346 |
| JardianceEmpagliflozin | 192 | $249,479 |
| MounjaroTirzepatide | 177 | $197,828 |
| FarxigaDapagliflozin Propanediol | 124 | $110,857 |
| TrulicityDulaglutide | 54 | $97,513 |
| Tresiba Flextouch U-100Insulin Degludec | 97 | $93,206 |
| JanuviaSitagliptin Phosphate | 70 | $76,338 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 253 | $70,132 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 28 | $61,790 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $59,854 |
| Novolog FlexpenInsulin Aspart | 161 | $59,203 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $55,393 |
| Humulin R U-500Insulin Regular, Human | 16 | $51,431 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $46,135 |
| Humalog Kwikpen U-100Insulin Lispro | 98 | $41,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Fiasp | $295 | $752,721550 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $512 | $309,956263 claims |
| Boehringer IngelheimJardiance, Tradjenta | $174 | $266,765212 claims |
| AstraZenecaFarxiga | $118 | $110,857124 claims |
| MerckJanuvia | $19 | $76,33870 claims |
| AbbVieArmour Thyroid | $12 | $2,16538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 121 registered nurse providers in Michigan.
Other registered nurse in Brownstown
- Melissa GuenthardtManistee$24K
- Ashley PoirierLivonia$3K
- Jennifer DentlerKalamazoo$3K
- Christine MaloufDetroit$2K
- Leslie WeisenbergerOakley$2K
- Susanna SirianniDetroit$2K
- Deirdre DenholmWalled Lake$2K
- Heather ThornsberryDetroit$1K
- Heather IrishFlint$1K
- Teresa HegwoodDearborn$779
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.